Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective $\alpha_{1A}$-adrenergic receptor antagonist. It selectively inhibits receptors in the human prostate, leading to relaxation of smooth muscle in the bladder neck and prostate, thereby improving urine flow rate and reducing symptoms of benign prostatic hyperplasia (BPH).
## Primary Indications
* Treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Medical expulsion therapy for ureteral calculi (distal stones).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily. May increase to 0.8 mg once daily if no improvement after 2–4 weeks.
* **Ureteral Calculi (off-label):** 0.4 mg orally once daily.
## Pediatric Dosing
* **Not indicated.** Safety and efficacy have not been established in pediatric populations.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required. Not recommended in patients with severe renal impairment (CrCl <10 mL/min) as clinical data is limited.
* **Hepatic Impairment:** Not recommended in severe hepatic impairment (Child-Pugh grade C). No adjustment needed for mild to moderate impairment.
## Contraindications
* Known hypersensitivity to tamsulosin or any component (e.g., sulfonamide allergy considerations, though risk is theoretical/low).
* History of angioedema.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde or decreased volume), rhinitis, orthostatic hypotension.
* **Serious:** Severe hypotension/syncope (especially with the first dose), intraoperative floppy iris syndrome (IFIS) during cataract surgery, priapism (rare).
## Key Drug Interactions
* **Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin):** May significantly increase tamsulosin levels; avoid or monitor closely.
* **Moderate CYP3A4 inhibitors (e.g., erythromycin, diltiazem):** Consider dose reduction if combined.
* **Other $\alpha$-blockers/Antihypertensives:** Potential for additive hypotensive effects.
* **PDE-5 Inhibitors (e.g., sildenafil, tadalafil):** Increased risk of symptomatic hypotension.
## Monitoring
* Monitor blood pressure periodically (especially during initiation or dose escalation).
* Assess symptom improvement via BPH symptom indices (e.g., IPSS).
* Monitor for signs of IFIS if the patient is scheduled for cataract surgery.
## Clinical Pearls
* **Administration:** Administer 30 minutes after the same meal each day. Do not crush, chew, or open the capsule.
* **Syncope Risk:** First-dose effect is possible; advise patients to rise slowly from a sitting or lying position.
* **Cataract Surgery:** Patients should inform their ophthalmologist of current or past tamsulosin use before surgery.
* **Selectivity:** Tamsulosin is more uroselective than non-selective alpha-blockers (e.g., terazosin) and typically does not require gradual dose titration for blood pressure management.
***
*Disclaimer: This information is for educational purposes and does not replace professional medical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors before administration.*
